Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

A concordance correlation coefficient to evaluate reproducibility.

Lin, L. I.-K. (1989) · Biometrics · doi:10.2307/2532051 · Cited by 8,785

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195

Response evaluations in non-small cell lung cancer patients undergoing immunotherapy: a comparative analysis of RECIST 1.1, iRECIST, and imRECIST criteria

Shih, Y.-J., Chen, J.-H., Yeh, L.-R., Lin, C.-Y., Huang, S., & Yang, C.-Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-03115-3 · Cited by 1

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0

McKay, R. R., Ajmera, A., Atkins, M. B., Barata, P. C., Bergerot, C. D., Bukavina, L., Choueiri, T. K., Desai, A., Hakimi, A. A., Poteat, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013788 · Cited by 5

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study

Sugimoto, K., Toyoda, S., Inoki, L., Mori, K., Yanagisawa, T., Tamura, K., Nukaya, T., Maenosono, R., Morinaka, H., Nishimura, S., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03075-2 · Cited by 1

IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model

Sobu, R., Kobayashi, Y., Kashima, S., Inoue, T., Sumiyoshi, T., Hamana, H., Takeda, M., Hiroshima, Y., Seki, S., Fujiyama, N., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116386 · Cited by 1

Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report

Nakanishi, Y., Kawashima, Y., Shinohara, M., Hagiwara, K., Inui, K., Ogawa, K., Fujimori, D., Moriyama, S., Oba, H., & Satoshi, S. (2026) · IJU Case Reports · doi:10.1002/iju5.70270 · Cited by 1

Critères de la réponse tumorale en imagerie : RECIST, mRECIST, Cheson

Fournier, L. S., Ammari, S., Thiam, R., & Cuénod, C. A. (2014) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2014.03.024 · Cited by 1

Moderne Diagnostik und standardisiertes Therapiemonitoring beim malignen Melanom

ten Persigehl, T., & Poeppel, T. D. (2016) · Forum · doi:10.1007/s12312-016-0131-8 · Cited by 1

Immunothérapie et évaluation de la réponse tumorale : la difficulté de la pseudoprogression

Loir, E., & Jouinot, A. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2661-1 · Cited by 1

Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma

Friedlander, P. A., Simpson, W., & Cajulis, C. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-29236-2_6 · Cited by 1

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?

Gupta, M., Choudhury, P., Jain, P., Sharma, M., Koyyala, V., Goyal, S., Agarwal, C., Jajodia, A., Pasricha, S., Sharma, A., et al. (2022) · World Journal of Nuclear Medicine · doi:10.1055/s-0042-1744201 · Cited by 1

Immune checkpoint inhibitors for advanced pancreatic cancer

Chan, W. Y., Sim, H., Haryono, M. A., Yip, D., & Chin, V. T. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014523 · Cited by 1

Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective

Ansari, G., Mirza‐Aghazadeh‐Attari, M., Mohseni, A., Madani, S. P., Shahbazian, H., Pawlik, T. M., & Kamel, I. R. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05762-1 · Cited by 1

Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma

Hara, T., Teishima, J., Okamura, Y., Suzuki, K., Bando, Y., Terakawa, T., Chiba, K., Hyodo, Y., Nakano, Y., & Miyake, H. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102236 · Cited by 1

T-Cell Responses During Cancer Immunotherapy Through the Use of CT, MRI, and PET

Soltani, A., Habibzadeh, A., Karimi, H., Afra, F., Eini, S., Nazari, H., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_423 · Cited by 1

Clinical trial end points relevant to patients and society for rare cancers

Khakoo, S. S., Georgiou, A., & Chau, I. (2015) · Clinical Investigation · doi:10.4155/cli.15.8 · Cited by 1

Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma

Lee, J. Y., Hong, B. S., Hong, B. S., Hong, J. H., Ahn, H., & Lee, J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3222-4 · Cited by 1

Resisting RECIST—Uniformity Versus Clinical Validity

Wilson, M. K., Friedlander, M. L., Lheureux, S., Small, W. C., Poveda, A. M., Pujade-Lauraine, É., Karakasis, K., Bacon, M. A., Bowering, V. L., Chawla, T. P., et al. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001062 · Cited by 1

Investigación de la eficacia y criterios de aprobación de los tratamientos con medicamentos para pacientes con cáncer: una revisión

Arango-Vélez, E., Hoyos, C. L. A., Tobón, J. J. Z., Restrepo-Ceballos, M., Lopera-Upegui, A., Zuluaga-Castellanos, H., Aguirre, J. P. B., & Pachón-Grajales, I. (2018) · IATREIA · doi:10.17533/udea.iatreia.v31n3a06 · Cited by 1

The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer

Gorospe, L., Pacios-Blanco, R. E., & Garrido, P. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2020.04.003 · Cited by 1

Response Evaluations for Precision Cancer Therapy and Immunotherapy

Nishino, M. (2020) · Medical radiology · doi:10.1007/978-3-030-31171-1_2 · Cited by 1

Radiologisches Monitoring bei Immuntherapie des Nierenzellkarzinoms

Lennartz, S., & ten Persigehl, T. (2021) · Aktuelle Urologie · doi:10.1055/a-1489-2163 · Cited by 1

The Future of Artificial Intelligence Applied to Immunotherapy Trials

Bodalal, Z., Trebeschi, S., Wamelink, I. J. H. G., Lipman, K. B. W. G., Bucho, T. M. T., van Dijk, N., Boellaard, T. N., Waktola, S., & Beets‐Tan, R. G. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_20 · Cited by 1

Checkpoint-Inhibitoren

Brossart, P., Grünwald, V., & Ochsenreither, S. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_54-1 · Cited by 1

Assessment of Treatment Outcome

Manola, J. B., Xu, W., & Giantonio, B. J. (2017) · TNM Online · doi:10.1002/9780471420194.tnmm05 · Cited by 1

Faculty Opinions recommendation of Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Hsu, V. W., & Li, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733785395.793556396 · Cited by 1

The caninized anti-canine PD-1 monoclonal antibody in canine oral malignant melanoma: Efficacy and exploratory biomarker analysisPreprint

Igase, M., Hagimori, K., Inanaga, S., Mizoguchi, H., ITAMOTO, K., Sakurai, M., Motegi, T., Yamamoto, H., Kato, M., Shiga, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.671889 · Cited by 1

Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade

Margolin, K. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0876

Assessment of treatment outcome

Manola, J. B., Xu, W., & Giantonio, B. J. (2015) · doi:10.1002/9781119013143.ch5

Reply to M. Nishino

Hodi, F. S., & Wolchok, J. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1097

Imaging of Tumor Response by Preoperative Systemic Treatment

Kanao, S., & Kataoka, M. (2016) · Springer eBooks · doi:10.1007/978-4-431-55552-0_18

Immunotherapy and non-small cell lung cancer: between lights and shadows

Bironzo, P., & Novello, S. (2016) · Cancer Breaking News · doi:10.19156/cbn.2016.0011

Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique

Ferretti, G., Reymond, E., Cohen, J., Jankowski, A., Levra, M. G., Toffart, A., & Moro‐Sibilot, D. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30121-5

The workflow of evaluation of drug efficacy and safety using medical imaging information in clinical trials

Yamamoto, S. (2016) · Medical Imaging and Information Sciences · doi:10.11318/mii.33.81

Immunotherapy for Renal Cell Cancer (RCC)

Kitano, S., Ito, A., & Kim, Y. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_12

Chimiothérapies personnalisées du cancer bronchique : ce que le radiologue doit connaître

Ferretti, G., Reymond, E., Delouche, A., Sakhri, L., Jankowski, A., Moro‐Sibilot, D., Lantuéjoul, S., & Toffart, A. (2017) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2017.04.002

Systems of response evaluation criteria in solid tumors in immunooncology treatment

Yudin, D. I., Павлович, Л. К., Саранцева, К. А., Chernenko, P., & Arzumanyan, A. L. (2017) · Malignant tumours · doi:10.18027/2224-5057-2017-1-42-46

Évaluation de la réponse thérapeutique après traitement par inhibiteurs des checkpoints (anticorps monoclonaux immunomodulateurs)

Fréneaux, E. (2017) · Médecine Nucléaire · doi:10.1016/j.mednuc.2017.06.005

Radiographic Evaluation of Immunotherapy

Feneis, J. F., Kligerman, S. J., & Weihe, E. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_4

"Tumor Response Evaluation after Treatment and Post-treatment Surveillance of Hepatocellular Carcinoma"

Yoon, J. S., & Park, S. Y. (2018) · Journal of Liver Cancer · doi:10.17998/jlc.18.1.9

iRECIST pour (pas seulement) les nuls

Menu, Y. (2019) · Journal d imagerie diagnostique et interventionnelle · doi:10.1016/j.jidi.2019.01.001

RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Novik, A. V. N., Yaremenko, E. V., Anokhina, E. M. A., Нехаева, Т. Л., Semenova, A. I. S., Латипова, Д. Х., Анатольевна, П. С., & Балдуева, И. А. (2019) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2019-18-4-13-20

Improving Clinical Trial Design in Gastrointestinal Oncology

Atasoy, A., & Mauer, M. E. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_28

Immune Checkpoint Inhibitors: Response Assessment and Immune-related Adverse Events

Zaman, M. U., & Fatima, N. (2019) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2019.10.907

Einfluss von Immunmodulatoren auf die urologische Bildgebung

Peisen, F., Thaiss, W. M., Tietze, N., Rausch, S., Amend, B., Nikolaou, K., Bedke, J., Stenzl, A., & Kaufmann, S. (2019) · Der Urologe · doi:10.1007/s00120-019-01063-1

Critères d’évaluation radiologique des patients sous immunothérapie

Wasielewski, E., Gauvain, C., & Cortot, A. B. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s2096-5192(19)30153-3

Evolution of Response Criteria in Immunotherapy

Liu, Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-31113-1_2

Therapy Response Imaging in Genitourinary Malignancies

Krajewski, K. M. (2020) · Medical radiology · doi:10.1007/978-3-030-31171-1_9

Therapy Response Imaging in Thoracic Malignancy

Nishino, M. (2020) · Medical radiology · doi:10.1007/978-3-030-31171-1_6

The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC)

Morbelli, S. D., Calcagni, M. L., Cistaro, A., Farsad, M., Guerra, L., Nanni, C., & Bianchi, A. (2020) · Clinical and Translational Imaging · doi:10.1007/s40336-019-00354-z

Response Assessment and Follow-Up by Imaging in Lung Tumours

Larici, A. R., Farchione, A., Cicchetti, G., del Ciello, A., Mantini, G., Terán, A. K. C., & Bolton, R. C. D. (2020) · Medical radiology · doi:10.1007/978-3-030-38261-2_23

The Role of Radiology in Immunotherapy Response Evaluation

Engin, G. (2020) · Turkish Journal of Oncology · doi:10.5505/tjo.2020.2294

EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY

Oganesian, A., Анатольевна, П. С., Балдуева, И. А., Semenova, A. I. S., Anokhina, Y., & Novik, A. (2020) · Voprosy Onkologii · doi:10.37469/0507-3758-2020-66-3-211-217

Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies

Uhlig, J., Biggemann, L., Sheth, A. H., & Sharma, R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1721404

Important Points to Consider When Evaluating the Response to Drug Therapy for Lung Cancer

Yabuuchi, H., Kamitani, T., Sagiyama, K., Yamasaki, Y., Hida, T., Matsuura, Y., & Ishigami, K. (2020) · Haigan · doi:10.2482/haigan.60.942

Apport de la TEP-TDM au 18F-FDG chez des patients avec cancer bronchique non à petites cellules ou mélanome métastatique traités par immunothérapie

Seban, R., Richard, C., Deleval, N., Edeline, V., & Champion, L. (2021) · Médecine Nucléaire · doi:10.1016/j.mednuc.2021.01.002

Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer

Ahuja, J., Shroff, G. S., Strange, C. D., Vlahos, I., Benveniste, M. F. K., & Truong, M. T. (2021) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2021.04.015

Artificial intelligence for imaging in immunotherapy

Trebeschi, S. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210322st

CT in Treatment Response Assessment in Oncology

Nathan, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-68858-5_2

Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings

Castello, A., & Lopci, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-68858-5_8

Molecular response assessment with immune adaptive positron emission tomography response criteria in solid tumors in lung cancer patients treated with nivolumab: Is it better than immune response evaluation criteria in solid tumors?

Gupta, M., Choudhury, P. S., Jain, P., Sharma, M. R., Koyyala, V. P. B., Goyal, S., Agarwal, C., Jajodia, A., Pasricha, S., Sharma, A., et al. (2022) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_58_21

Tumor pseudoprogression (lung cancer)

Botz, B., Campos, A., & Alsmair, A. (2022) · Radiopaedia.org · doi:10.53347/rid-96874

Methoden klinischer Prüfung in der Onkologie

Dittrich, C., Edler, L., & SINDERMANN, H. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_362-1

Assessing Response to Therapy

Virarkar, M., Macapinlac, H. A., Pokhylevych, H., & Bhosale, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00005-7

PET imaging of lung and pleural cancer

Giammarile, F., Pellet, O., Terán, A. K. C., & Bolton, R. C. D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00206-4

Ocena odpowiedzi w immunoterapii nowotworów. Współpraca onkolog-radiolog

Pałucki, J., & Kucharz, J. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0028

Melanoma

Faria, S. C., Amaria, R. N., & Patnana, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00037-9

irRC and irRECIST

(2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37706-5.50163-3

Gynecologic Malignancies

Starbuck, K. D., Mayor, P. C., & Zsíros, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00007-x

Faculty Opinions recommendation of T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Tsokos, G. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727496469.793570393

Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know

Cavallero, D., BORRI, F., Bruni, L., Chiellini, M., Cioni, D., & Neri, E. (2022) · Journal of Radiological Review · doi:10.23736/s2723-9284.22.00193-3

CPI Adult Cancer Imaging Special Edition Module

DiPiro, P. J., Salvo, D. N. D., Fennessy, F. M., Howard, S. A. H., Jacene, H. A., Krajewski, K. M., Shinagare, A. B., & Tirumani, S. H. (2019) · doi:10.54057/cpi.ac2019

PD-L1 on lymphatic endothelium inside tumor: a novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 antibodyPreprint

Zhang, C., Chu, T., Wang, Q., Cheng, Y., Zhang, Y., Wang, R., Han, B., & Li, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1902043/v1

Invited Commentary: Pearls and Pitfalls in Imaging Evaluation of Lung Cancer Immunotherapy

Nishino, M. (2022) · Radiographics · doi:10.1148/rg.220170

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

Николаевна, Б. Н., Дронова, Т. А., Анатольевна, Г. П., Popova, N. O., Dobrodeev, А. Y., Костромицкий, Д. Н., Afanasyev, S. G., Goldberg, V. E., & Чердынцева, Н. В. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-5-135-141

Radiologic assessment of tumor response to immunotherapy and its complications

Roshkovan, L., & Katz, S. I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00019-7

Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Verset, G., Borbath, I., Karwal, M., Verslype, C., Vlierberghe, H. V., Kardosh, A., Zagonel, V., Stal, P. I., Sarker, D., Palmer, D. H., et al. (2023) · doi:10.1158/1078-0432.22487751.v1

Data from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Glisson, B. S., Leidner, R. S., Ferris, R. L., Powderly, J. D., Rizvi, N. A., Keam, B., Schneider, R., Goel, S., Ohr, J. P., Burton, J., et al. (2023) · doi:10.1158/1078-0432.c.6529643

Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M. J., Blinder, V. S., Brahmachary, M., Carlsen, M., Comen, E. A., et al. (2023) · doi:10.1158/1078-0432.c.6529578

Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M. J., Blinder, V. S., Brahmachary, M., Carlsen, M., Comen, E. A., et al. (2023) · doi:10.1158/1078-0432.c.6529578.v1

Data from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Glisson, B. S., Leidner, R. S., Ferris, R. L., Powderly, J. D., Rizvi, N. A., Keam, B., Schneider, R., Goel, S., Ohr, J. P., Burton, J., et al. (2023) · doi:10.1158/1078-0432.c.6529643.v1

Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Verset, G., Borbath, I., Karwal, M., Verslype, C., Vlierberghe, H. V., Kardosh, A., Zagonel, V., Stal, P. I., Sarker, D., Palmer, D. H., et al. (2023) · doi:10.1158/1078-0432.22487751

Iatrogenic Conditions

Palacio, D. M., Jayagurunathan, U., Shroff, G. S., de Groot, P. M., Truong, M. T., & Moran, C. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-21040-2_26

Cancer immunotherapy in second-line treatment of non-small cell lung cancer – is there a need to change the approach to the assessment of clinical benefits?

Panasiuk, A., Budasz-Świderska, M., & Kaczor, M. (2018) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2017.2.9

Supplementary Materials 1 from A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma

Lee, Y. B., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, H., Paeng, J. C., Yoon, J., & Kim, Y. J. (2023) · doi:10.1158/1078-0432.23905303

Supplementary Materials 1 from A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma

Lee, Y. B., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, H., Paeng, J. C., Yoon, J., & Kim, Y. J. (2023) · doi:10.1158/1078-0432.23905303.v1

Imaging Assessment of Tumoral Response After Immunotherapy

Zanon, C., & Quaia, E. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_135-1

Supplementary Materials 1 from A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma

Lee, Y. B., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, H., Paeng, J. C., Yoon, J., & Kim, Y. J. (2023) · doi:10.1158/1078-0432.24146043.v1

Supplementary Materials 1 from A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma

Lee, Y. B., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, H., Paeng, J. C., Yoon, J., & Kim, Y. J. (2023) · doi:10.1158/1078-0432.24146043

Immunotherapy

Viscardi, G., Russo, G. L., Ferrara, R., & Garassino, M. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00022-x

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon

Amrane, K., Meur, C. L., Thuillier, P., Kamga, J. D., Alemany, P., Chauvelot, F., Niel, C., Bellange, A., & Abgral, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243208

Bildgebung bei Immuntherapie bei Tumorerkrankungen

Sedlaczek, O. (2024) · Die Radiologie · doi:10.1007/s00117-023-01248-y

[Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].

Tong, Y., Long, Y., Zhang, F., & Li, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.101.10

Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance

Scafetta, R., Carnevale, A., Castellano, G., Giugliano, F., Santoro, C., Scalia, R., Trapani, D., & Curigliano, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00008-3

Immunotherapy for advanced and recurrent malignant pleural mesothelioma

Haugaard, A. K., Conde, R. S., Maria, A. R. J., Yergolkar, A. V., Jørgensen, K. J., & Heleno, B. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014720

Critères d’évaluation de la TEP au 18F-FDG au cours de l’immunothérapie

Hamdan, D., Anjorand, E., Bousquet, G., & Soussan, M. (2024) · Médecine Nucléaire · doi:10.1016/j.mednuc.2024.10.005

Clinical Implications of Mixed Response on Prognosis of Non-Small Cell Lung Cancer (Nsclc) Patients Treated with ImmunotherapyPreprint

Lee, S., Chae, Y. K., Um, T., Lee, J., Jung, C. M., Shin, C., Kim, P. H., Yadav, M., Chuchuca, M. J. A., & Chung, L. I. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5046517

Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy

Horisaki, K., Yoshikawa, S., Omata, W., Tsutsumida, A., & Kiyohara, Y. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17938

Imaging Assessment of Tumoral Response After Immunotherapy

Zanon, C., & Quaia, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-00763-6_135

Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors

Omori, M., Komatsu, S., Tada, T., Ishihara, N., Matsuura, T., Ueshima, E., Fujishima, Y., Ishihda, J., Kido, M., Gon, H., et al. (2025) · HPB · doi:10.1016/j.hpb.2025.11.008

Additional file 4 of Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Zhang, Z., Xie, C., Gao, T., Yang, Y., Yang, Y., & Zhao, L. (2023) · Figshare · doi:10.6084/m9.figshare.22614643

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Nishino, M., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-17 · Cited by 95

Radiological Measurement of Breast Cancer Metastases to Lung and Liver: Comparison Between WHO (Bidimensional) and RECIST (Unidimensional) Guidelines

Prasad, S. R., Saini, S., Sumner, J. E., Hahn, P. F., Sahani, D. V., & Boland, G. W. (2003) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-200305000-00014 · Cited by 41

RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma

Assouline, S. E., & Eisenhauer, E. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.6606 · Cited by 1

RESEARCH ARTICLE Open Access Optimizing immune-relate g e

(2016)

[Response criteria for malignant melanoma: RECIST and irRC].

Spiro, J., Maintz, D. C., & ten Persigehl, T. (2015) · PubMed · doi:10.1007/s00117-014-2763-y · Cited by 7